Medias Health Inc.

Medias Health has being establishing itself in a role of Mergers and Acquisitions Advisory and Consultancy in the biopharma and biotech markets. New and exciting developments are on the way. Stay tuned!

Global breast cancer study reveals 72 new mutations
http://www.oncotherapynetwork.com/breast-cancer-targets/global-breast-cancer-study-reveals-72-new-mutations/?GUID=1888105C-CA53-42D5-ADF5-4686630F5222&rememberme=1&ts=07122017

www.oncotherapynetwork.com

Our press release is out!
http://www.newswire.ca/news-releases/internationally-renowned-oncologist-and-a-company-with-new-radical-cancer-drugs-to-speak-and-present-in-toronto-at-the-5th-annual-after-breast-cancer-pink-diamond-gala-646370943.html

Internationally Renowned Oncologist and a Company with New Radical Cancer Drugs to Speak and Present in Toronto at the 5th Annual after Breast Cancer Pink Diamond Gala TORONTO, Sept. 21, 2017 /CNW/ - Medias Health Inc. is pleased to announce that it is presenting an esteemed surgical...

We are continuing our work on creating awareness around new and alternative methods of fighting cancer. Please share this latest video from our Project. Thank you!
https://youtu.be/p56-Xa-6euw

#DamageCancer Medias Health A short video in support of Medias Health campaign and efforts.

Breaking: Medias Health Inc. is pleased to announce its support for and participation in the After Brest Cancer (ABC) Foundation annual Pink Diamond Gala 2017. This event will take place on September 24, 2017. As a partner of ABC, Medias Health invited Prof. Dr. med. Karl. R. Aigner, a leading specialist in Regional Chemotherapy (RCT) cancer treatment, as a keynote speaker for the event. As well, we will be introducing Tyme Inc. and their unique and very promising oncological product SM-88 (in medical trial in the USA and first time in Canada). Please note that after the Gala, there will be a Q&A session and presentation by Prof. Aigner about his work with RCT and by Tyme Inc. about their progress with SM-88. Information about purchasing tickets is at the link below:
http://afterbreastcancer.ca/gala/

Annual Pink Diamond Gala – Support after BREAST CANCER Just another WordPress site

You will find a lot of information about regional chemotherapy cancer treatment, including articles, interviews and testimonials from current patients. Visit https://regionalchemotherapy.com

Breaking: On September 24, 2017, Medias Health inc. is partnering with After Brest Cancer Foundation in support of its annual Pink Diamond Gala 2017. We are pleased to bring Prof. Dr. med. Karl. R. Aigner, a leading specialist in Regional Chemotherapy cancer treatment, as a keynote speaker for the event. As well, we will be introducing Tyme Inc. and their unique and very promising oncological product SM-88 (in medical trial in the USA). After the gala, there will be a Q&A session and presentation by Prof. Aigner and Tyme Inc. Information about purchasing tickets is at the link below:
http://afterbreastcancer.ca/gala/

Annual Pink Diamond Gala – Support after BREAST CANCER Just another WordPress site

Making experimental cancer treatment decision with limited amount of information when a stage-4 cancer patient is running out of time is hard. Treatment options for cancer, including standard and experimental cancer treatments, are not limited to one or two isolated therapies.
https://regionalchemotherapy.com/making-experimental-cancer-treatment-decision/

Making experimental cancer treatment decision - Regional Chemotherapy Making experimental cancer treatment decision with limited amount of information when a stage-4 cancer patient is running out of time is hard.

A distinct advantage of regional chemotherapy in all of its variants is that it increases the concentration of the drugs in the cancer-affected area. Often higher concentration of the drug equates to higher efficacy, improving cancer therapy benefits. Furthermore, regional chemotherapy aims to reduce the exposure of additional tissues to the chemotherapy agents, thus, minimizing the risk of severe adverse effects.
https://regionalchemotherapy.com/improving-cancer-therapy-benefits/

Improving Cancer Therapy Benefits: Combining Regional Chemotherapy and Standard Treatments - Regional Chemotherapy One advantage of regional chemotherapy is that it increases the concentration of the drugs in the cancer-affected area, improving cancer therapy benefits.

It is hard to think about the experimental cancer treatment cost for anyone who is fighting a terrible disease like cancer. However, affordability of cancer treatments, and particularly alternative cancer treatments is an important subject.
https://regionalchemotherapy.com/experimental-cancer-treatment-cost-benefit-analysis/

Experimental cancer treatment cost benefit analysis - Regional Chemotherapy It is hard to think about the experimental cancer treatment cost for anyone who is fighting a terrible disease like cancer.

RCT is not a new treatment protocol. However, in some applications it is an experimental treatment, and very few medical teams can perform such therapies.
https://regionalchemotherapy.com/standard-cancer-treatment-fails-whats-next/

If standard cancer treatment fails, what’s next? - Regional Chemotherapy When standard cancer treatment fails, many patients and their families start anew, searching for alternatives, including experimental treatments.

Selecting a new treatment option and finding the means to pay for it, are some of the decisions by those who are fighting. Whatever the decisions are, more often than not, they demand hard choices. Furthermore, these choices often have to be made fast, sometimes very fast, while looking into the eyes of ultimate uncertainty.
https://regionalchemotherapy.com/making-hard-decisions-fighting-cancer/

Making Hard Decisions Fighting Cancer - Regional Chemotherapy Experimental cancer treatments affordability is a big issue. It is inevitable that individuals with cancer will be making hard decisions fighting cancer.

Because experimental cancer treatments stand outside of standard regiments and treatment protocols, they are usually the last in the line of therapy options. Only when conventional methods of cancer treatment fail, most patients resort to experimental cancer treatments. Despite the status of being experimental, in many cases experimental cancer treatments can be an important resource in the arsenal available to cancer patients. Follow the link below to read more.
https://regionalchemotherapy.com/experimental-cancer-treatment/

Experimental Cancer Treatment - Regional Chemotherapy Because experimental cancer treatments stand outside of standard regiments and treatment protocols, they are usually the last in the line of options.

A cancer patient journey to the right treatment can be defined in five phases. It starts with awareness and recognition phase, and moves to presentation and diagnosis phase. Following those two, are treatment selection phase and access to treatment. Finally, switching and persistence complete the journey and help to ensure its effectiveness.
https://regionalchemotherapy.com/cancer-patient-journey/

Cancer Patient Journey - Regional Chemotherapy Even today, a cancer patient journey to the right treatment can be less then optimal, despite all the advances in technology and medicine.

Just like the impatient and insubordinate ninja warriors, new cancer treatment therapies suddenly appear hear and there. Just like the insolent ninjas in training, some of these cancer treatments show good strength and results in their fights with cancers. Regional Chemotherapy (RCT) is one such irreverent cancer fighting ninja.
https://regionalchemotherapy.com/cancer-fighting-ninja/

Cancer Fighting Ninja - Regional Chemotherapy Regional Chemotherapy (RCT) is one such irreverent cancer fighting ninja. It is powerful, focused and can be deadly to many tumors.

Regional chemotherapy success in treating deadly cancer.
A recent peer reviewed paper on the use of Isolated Thoracic Perfusion (a form of Regional Chemotherapy) in treating progressive malignant pleural mesothelioma has been published. Progressive malignant pleural mesothelioma is the type of lung cancer with links to asbestos. This cancer is currently considerate incurable and has limited treatment options.
The medical team of Prof. Karl R. Aigner, Dr. Emir Selak and Dr. Sabine Gailhofer have conducted the study at the Department of Surgical Oncology at Medias Klinikum and produced the paper. The paper has been single blind peer reviewed and approved by Dr. Amy Norman and editor Dr. Ingrid Espinoza.
https://regionalchemotherapy.com/treating-progressive-malignant-pleural-mesothelioma/

Treating progressive malignant pleural mesothelioma - Regional Chemotherapy A peer reviewed paper on the use of Isolated Thoracic Perfusion (a form of Regional Chemotherapy) in treating progressive malignant pleural mesothelioma.

The debate about alternative cancer treatment versus standardized treatment protocols is nothing new. Considering that at stake are lives, it is as acute today as it has ever been.
https://regionalchemotherapy.com/trying-alternative-cancer-treatment-methods/

Reasons for Trying Alternative Cancer Treatment Methods - Regional Chemotherapy Only when it is clear that the disease does not respond to the orthodox treatment protocols, the need for alternative cancer treatment methods emerges.

In some case hyperthermia can offer better outcomes when combined with regional chemotherapy or other cancer treatments.
https://regionalchemotherapy.com/treatments/hyperthermia-cancer-treatment/

Hyperthermia in Cancer Treatment - Regional Chemotherapy The following treatment enhancing procedures are available in combination with Regional Chemotherapy: Deep and whole-body hyperthermia cancer treatments

Study: A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer (seven-gene test).

"An estimate for 2015 predicted 231,840 new cases of breast cancer and 40,290 breast cancer deaths in the USA. Women with a family history of breast cancer are at increased
risk, with about 13% of women with breast cancer having one or more first-degree relatives with the disease.

Pathogenic variants in the BRCA1 and BRCA2 genes explain approximately 15% of the breast cancer familial relative risk (i.e., the ratio of the risk of an individual with an affected relative to the risk of individuals in the general population), whereas pathogenic variants in other genes, including TP53, PTEN, CDH1, and PALB2, contribute further to the familial relative risk for breast cancer." https://www.ispor.org/economic-evaluaiton_life-expectancy-women_breast-cancer.pdf

www.ispor.org

The first week of summer.

Study helps to explain acquired resistance among cancer patients treated with immune checkpoint blockade drugs for the treatment of lung cancer and a number of other cancers.
https://www.sciencedaily.com/releases/2017/01/170105133836.htm

Cancers evade immunotherapy by 'discarding the evidence' of tumor-specific mutations: Discovery could explain widespread acquired resistance among patients treated with immune checkpoint blockade drugs Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination of certain genetic mutations needed to enable the immune system to recogniz...

1 in 7 men will get a prostate cancer. That is chilling statistics. Ben Stiller was not speared, despite his celebrity status. Listen to what he has to say in this candid interview.
http://www.today.com/video/ben-stiller-on-prostate-cancer-and-the-psa-test-every-guy-should-get-tested-815118915716

Ben Stiller on prostate cancer and the PSA test: ‘Every guy should get tested’ Just last month, actor Ben Stiller revealed he was diagnosed and treated for prostate cancer two years ago, at the age of 48. Now he joins TODAY’s Matt Lauer along with his surgeon, Dr. Edward Schaeffer, to talk about the controversial prostate-specific antigen (PSA) test. He also reveals why he opt...

The cutest odd couple. They look completely uninterested in each other.

Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival
http://www.sciencedirect.com/science/article/pii/S0748798317300598

Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival Synopsis: Malignant peritoneal mesothelioma was treated over a 20 year time period with a consistent surgical procedure followed by an escalation of regional chemotherapy treatments. When regional chemotherapy long term was added to the treatment plan survival improved significantly (p = 0.0108).

"The new phase I pilot study (PLAT-03) will examine the feasibility and safety of administering a second T-cell product intended to increase the long-term persistence of the patient’s CAR (Chimeric antigen receptor) T cells that were reprogrammed to detect and destroy cancer. "
http://www.oncotherapynetwork.com/hematologic-cancer-targets/improving-car-t-cell-immunotherapy-children-young-adults

Improving CAR T-Cell Immunotherapy in Children, Young Adults | OncoTherapy Network Researchers at Seattle Children's Research Institute announced the first-in-human clinical trial aimed to extend remission for children and young adults with leukemia treated with CAR T-cell immunotherapy.

Intravasation is the invasion of cancer cells through the basal membrane into a blood or lymphatic vessel. Intravasation is one of several carcinogenic events that initiate the escape of cancerous cells from their primary sites.
Researchers in California may have discovered why some cancers reoccur after years in remission. In their study they demonstrate how invasive tumors may begin intravasation much earlier than was previously thought.
http://www.cell.com/cell-reports/fulltext/S2211-1247(17)30425-4

Intratumoral Cancer Cell Intravasation Can Occur Independent of Invasion into the Adjacent Stroma Deryugina and Kiosses investigate the localization of intravasation within primary tumors. They find that the majority of intravasation events occur within the tumor core and not at the invasive edge within tumor outgrowths into adjacent stroma in the models examined. Mechanistically, EGFR appears t...

We all benefit from a healthy diet, but for people fighting cancer it is a must.

Another study validates Regional chemotherapy for extremity sarcoma treatment. In this study amputations were avoided and limbs were salvaged in 77.9% of the cases.
https://www.sciencedaily.com/releases/2017/02/170215121013.htm

Regional chemotherapy technique for extremity sarcoma salvages limbs from amputation: Study reports nearly 80 percent limb preservation rate for cancers that typically lead to amputation Patients with a type of advanced malignant cancer of the arms or legs have typically faced amputation of the afflicted limb as the only treatment option. However, a technique that limits the application of chemotherapy to the cancerous region can preserve limbs in a high percentage of these patients...